

● Neglected Tropical Diseases

# Eliminating sleeping sickness by 2030

*Supporting broader global efforts to fight NTDs*

Our vision to 2030 is to revolutionize the treatment landscape for vulnerable communities, making the sustainable elimination of sleeping sickness a tangible reality.



# The battle against *sleeping sickness*

 *Harnessing innovation and partnerships to overcome Neglected Tropical Diseases*

Sleeping sickness, or Human African trypanosomiasis (HAT), poses a significant threat in remote African communities. This fatal disease, caused by parasites transmitted by tsetse flies, requires urgent treatment.

Despite a significant reduction in cases thanks to improved control and treatment options, the complexity of administering these treatments remains a hurdle in hard-to-reach populations.

Foundation S' work on sleeping sickness is supported by strong public and private partnerships, including our long-term collaboration with WHO and the non-profit Drugs for Neglected Diseases Initiative (DNDi).

This cooperative approach is pivotal in revolutionizing the treatment landscape, ensuring sustainable access to care, and aligning with WHO's ambitious goal of eliminating sleeping sickness by 2030.



Our strategy focuses on:

## *Saving Lives*

Collaborating with WHO, we are dedicated to ensuring that every patient with sleeping sickness can access safer and more effective medicines.

## *Innovating for the Vulnerable*

In partnership with DNDi, we aim to introduce Acoziborole as a novel and effective treatment for adult patients.

Our ambitions will be pursued through educational programs, drug donations, and the development of new, simplified treatment methods.



Foundation S, Sanofi, WHO and DNDi developed fexinidazole, the first-ever complete multi-dose oral treatment for sleeping sickness.



Building on this success, we are now focused on introducing an investigational innovative single-dose oral treatment (Acoziborole) for patients.

# Over the last decade, the fight against sleeping sickness has undergone a *transformative shift* towards elimination and better treatment access

Central to this shift are collaborations between Foundation S, Sanofi, WHO, DNDi, Médecins Sans Frontières, and national sleeping sickness control programs in the Democratic Republic of the Congo and Guinea, among others.

This coalition has adopted a multi-faceted approach, integrating sleeping sickness control into national health systems. Efforts include raising awareness, training health workers, advancing treatments through research and innovation, and maintaining a stable supply chain.

Sanofi and Foundation S have been instrumental in ensuring medication supply, especially to remote regions typically overlooked by the pharmaceutical market. Their 20-year partnership with WHO has significantly contributed to a 97% drop in global cases since the early 2000s, moving the world closer to eliminating sleeping sickness – a historic feat potentially achievable without a vaccine. This ongoing commitment underscores the power of global collaboration in public health.



Angola, Cameroon, the Central African Republic (CAR), Chad, the Republic of the Congo, the Democratic Republic of Congo (DRC), Equatorial Guinea, Gabon, Guinea, and South Sudan have successfully integrated fexinidazole into their treatment protocols.

Togo, Cote d'Ivoire, Benin, Uganda, Equatorial Guinea, and Ghana have proudly announced their success in eliminating the Gambiense strain of sleeping sickness, while Rwanda has shown progress in eliminating the Rhodesiense strain.



# Foundation S, Sanofi and DNDi: *a longstanding partnership*

Foundation S, Sanofi, and DNDi form an important alliance in the fight to eliminate sleeping sickness by 2030. In November 2022, we announced the successful trial of Acoziborole, a single-dose oral treatment for the disease. If approved, Acoziborole will be a game-changer, simplifying treatment with its one-day treatment and enabling a ‘screen-and-treat’ approach, which is crucial for remote and underserved communities.

This breakthrough, due to DNDi’s extensive research and Sanofi’s production expertise, represents *a significant step towards eliminating sleeping sickness* and making treatment more accessible and efficient for all, especially children.

“

*“The word alliance is stronger than partnerships. This alliance is moved by a common vision - elimination of the disease. We take risks individually and together.”*

DNDi, partner

“

*“We, together with Sanofi, the Gates Foundation and the health ministries gradually developed a drug that today is a pill that you take for 10 days and it cures you completely. Imagine the change. And we hope very soon (we already have very good results) to be able to move to a one-day pill and cure people definitively. Thanks to this we hope to eliminate sleeping sickness completely in a few years.”*

Luis Pizarro, DNDi CEO



Three young children playing in Malawi



# Looking forward

Our overarching goal for NTDs and sleeping sickness in 2024 is to expand the scope of our battle against NTDs while reinforcing collaborative efforts through community-led initiatives and global partnerships.

→ ***Securing regulatory approval for Acoziborole:***


We will continue to work towards this significant milestone in eliminating sleeping sickness.

→ ***Proactively addressing the impact of climate change on NTDs through community-based projects:***

We will work and speak with communities directly and create sustainable solutions at the grassroots level, recognizing the interconnectedness of environmental factors and public health.

→ ***Reinforcing our partnerships with global actors to address other NTDs:***

We will significantly emphasize reinforcing partnership channels on NTDs beyond sleeping sickness.

A woman in a colorful patterned dress is walking away from the camera, carrying a bright green bucket. She is in a rural setting with a dirt road. In the background, there are several white vans parked, and a building with a corrugated metal roof. The scene is brightly lit, suggesting a sunny day.

*Sleeping sickness remains a health challenge in Malawi*